Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D76INB
|
|||
Drug Name |
Tesidolumab
|
|||
Synonyms |
LFG316
Click to Show/Hide
|
|||
Drug Type |
Antibody
|
|||
Indication | Age-related macular degeneration [ICD-11: 9B75.0; ICD-10: H35] | Phase 2 | [1] | |
Company |
Novartis
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Complement C5 (CO5) | Target Info | Inhibitor | [2] |
KEGG Pathway | Complement and coagulation cascades | |||
Prion diseases | ||||
Pertussis | ||||
Staphylococcus aureus infection | ||||
Herpes simplex infection | ||||
Systemic lupus erythematosus | ||||
Reactome | Activation of C3 and C5 | |||
Peptide ligand-binding receptors | ||||
G alpha (i) signalling events | ||||
Regulation of Complement cascade | ||||
WikiPathways | Complement Activation, Classical Pathway | |||
Human Complement System | ||||
Spinal Cord Injury | ||||
Allograft Rejection | ||||
GPCR ligand binding | ||||
GPCR downstream signaling | ||||
Complement cascade |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT01527500) Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD). U.S. National Institutes of Health. | |||
REF 2 | Intravenous immunoglobulin significantly reduces exposure of concomitantly administered anti-C5 monoclonal antibody tesidolumab. Am J Transplant. 2020 Sep;20(9):2581-2588. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.